Business
Axsome Therapeutics Presents New AUVELITY® Data in Major Depressive Disorder at the American Society of Clinical Psychopharmacology (ASCP) 2026 Annual Meeting
NEW YORK, May 26, 2026 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced presentations of new AUVELITY® data in major depressive disorder at the American Society of Clinical Psychopharmacology (ASCP) 2026 Annual Meeting being held from May 26-29 in Miami, FL. Details of the presentations are as follows: Title: Effects of Dextromethorphan-Bupropion (45 mg/105 mg) i
About this update from Axsome Therapeutics, Inc.
[{"type":"image","alt":"Axsome Therapeutics, Inc.","displaySize":"","headline":null,"caption":"Axsome Therapeutics, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":198,"url":"https://media.zenfs.com/en/globenewswire.com/f877923e5fbf4e5fb0d5937a043d2467"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/vRTxlCkoAGJ1bw.3TR0iDw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTI3Nw--/https://media.zenfs.com/en/globenewswire.com/f877923e5fbf4e5fb0d5937a043d2467","width":300,"height":198},"resize_sm":{"url":"https://s.yimg.com/ny/api/res/1.2/vRTxlCkoAGJ1bw.3TR0iDw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTI3Nw--/https://media.zenfs.com/en/globenewswire.com/f877923e5fbf4e5fb0d5937a043d2467","width":300,"height":198}},"lazy":false},{"type":"text","content":"NEW YORK, May 26, 2026 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced presentations of new AUVELITY® data in major depressive disorder at the American Society of Clinical Psychopharmacology (ASCP) 2026 Annual Meeting being held from May 26-29 in Miami, FL.","length":393,"tagName":"p"},{"type":"text","content":"Details of the presentations are as follows:","length":44,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Title: Effects of Dextromethorphan-Bupropion (45 mg/105 mg) in Participants with Major Depressive Disorder and Anxious DistressPresentation Date and Time: Wednesday, May 27, 11:45 a.m. - 1:30 p.m. ETLead Author: Jeffrey R. Strawn, MD, Professor of Psychiatry and Behavioral Neuroscience, University of Cincinnati, OHPoster Number: W42","length":337,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":337,"olType":false},{"type":"list","items":[{"val":[{"type":"text","content":"Title: Anxiolytic Effects of Dextromethorphan-Bupropion (45 mg/105 mg): Post Hoc Analyses Across Trials in Major Depressive DisorderPresentation Date and Time: Wednesday, May 27, 11:45 a.m. - 1:30 p.m. ETLead Author: Jeffrey R. Strawn, MD, Professor of Psychiatry and Behavioral Neuroscience, University of Cincinnati, OHPoster Number: W50","length":342,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":342,"olType":false},{"type":"list","items":[{"val":[{"type":"text","content":"Title: Real-World Clinical Outcomes of Patients ...